Company intelligence / Profile preview
Type6 Therapeutics
South San Francisco, California, United Statestype6tx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Type6 Therapeutics develops first-in-class small molecule therapeutics that target disease-driving kinases at their most vulnerable "OFF-state," aiming to overcome resistance mechanisms in aggressive cancers. Their lead program focuses on a novel CDK2 inhibitor with preclinical proof-of-concept. The company’s approach offers unmatched selectivity and durability compared to traditional ON-state kinase inhibitors. Additional programs are being developed against other high-value kinase targets using the same proprietary platform.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule kinase inhibitorsAntibody-drug conjugates (ADCs)Bifunctional/bivalent small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Type6 Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Type6 Therapeutics.